ContextVision announces first CE marked digital pathology product
STOCKHOLM – June 29, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced that its first digital pathology product in a planned portfolio has been granted CE mark status. This means that INIFY[®] Prostate Screening is now available for routine clinical use within the European Union. “I am proud of the great performance by our outstanding multidisciplinary team in reaching this company milestone. Healthcare systems around the world are already under great stress due to heavy workloads and lack of resources –